Evidence Hub

Outcomes for Sinonasal Undifferentiated Carcinoma (SNUC): An International Multi-Center Retrospective Cohort Study

Jacklyn Liu, Y. Takahashi, U. Rehman, M. Turri-Zanoni, D. Mattavelli, N. Counsell, M. Ferrari, V. Rampinelli et al.

Cancers, 2026

485 participants · 1 citation

Abstract

Simple Summary Sinonasal undifferentiated carcinoma (SNUC) is a very rare and aggressive cancer that arises from the nasal cavity and paranasal sinuses. Due to its rarity, there are no established standards of treatment. Patients often present with a disease that has advanced into adjacent organs such as the eye and the brain, as well as distant spread into organs such as the liver or lung. This study collected information from 485 patients from multiple countries across three continents to examine treatment paradigms in several global centers of excellence, studying factors that may influence patient survival. This study found that involvement of the orbit and the presence of distant spread were associated with worse outcomes, and found that traditional tumor classification and staging measures were less predictive. These findings provide valuable insights into the need for redefining a staging system that may more accurately prognosticate and stratify treatment escalation strategies.

How strong is the evidence?

Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 485 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free